The controversial diabetes drug Avandia, currently damaged by a report published in the New England Journal of Medicine and a subsequent Food and Drug Administration warning, could come through the mire unscathed, accord to Glaxo bosses.
The chief executive of GSK, Jean-Pierre Garnier, reportedly commented that the possibility does exist for sales of Avandia to recover lost ground once the company reveals safety data proving the healthcare efficacy of the drug.
The study that gave rise to the storm indicated that Avandia gave diabetic patients a 43 per cent higher risk of heart attack. Glaxo admit that their research shows a 30 per cent increased risk of heart attack, but that the FDA was well aware of this.
Whether or not the company face lawsuits over the drug remains to be seen.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…